Precision Medicine into Clinical Practice: A Web-Based Tool Enables Real-Time Pharmacogenetic Assessment of Tailored Treatments in Psychiatric Disorders

The management of neuropsychiatric disorders involves different pharmacological treatments. In order to perform efficacious drug treatments, the metabolism of CYP genes can help to foresee potential drug–drug interactions. The NeuroPGx software is an open-source web-based tool for genotype/diplotype/phenotype interpretation for neuropharmacogenomic purposes. The software provides information about: (i) the genotypes of evaluated SNPs (single nucleotide polymorphisms); (ii) the main diplotypes in CYP genes and corresponding metabolization phenotypes; (iii) the list of neuropsychiatric drugs with recommended dosage adjustment (according to CPIC and DPWG guidelines); (iv) the list of possible (rare) diplotypes and corresponding metabolization phenotypes. The combined application of NeuroPGx software to the OpenArray technology results in an easy, quick, and highly automated device ready to be used in routine clinical practice.

[1]  E. Corruble,et al.  Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants , 2021, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[2]  G. Corrivetti,et al.  Pharmacogenetics of Carbamazepine and Valproate: Focus on Polymorphisms of Drug Metabolizing Enzymes and Transporters , 2021, Pharmaceuticals.

[3]  I. Jang,et al.  Pharmacogenomic information from CPIC and DPWG guidelines and its application on drug labels , 2020, Translational and clinical pharmacology.

[4]  V. Solhaug,et al.  Impact of CYP2D6 on serum concentrations of flupentixol, haloperidol, perphenazine and zuclopenthixol , 2020, British journal of clinical pharmacology.

[5]  A. Gaedigk,et al.  The Respective Roles of CYP3A4 and CYP2D6 in the Metabolism of Pimozide to Established and Novel Metabolites , 2020, Drug Metabolism and Disposition.

[6]  Dai Zhang,et al.  CYP2D6 Genotype-Based Dose Recommendations for Risperidone in Asian People , 2020, Frontiers in Pharmacology.

[7]  J. Bishop,et al.  CYP2D6 Genetic Polymorphisms and Risperidone Pharmacokinetics: A Systematic Review and Meta‐analysis , 2020, Pharmacotherapy.

[8]  V. Liu,et al.  Associations of CYP2C9 and CYP2C19 Pharmacogenetic Variation with Phenytoin‐Induced Cutaneous Adverse Drug Reactions , 2020, Clinical and translational science.

[9]  Aripiprazole , 2019, Reactions Weekly.

[10]  K. Bailey,et al.  Clopidogrel Pharmacogenetics: State-of-the-Art Review and the TAILOR-PCI Study , 2019, Circulation. Cardiovascular interventions.

[11]  D. Ochoa,et al.  Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics , 2019, Journal of psychopharmacology.

[12]  D. Tolbert,et al.  A Comprehensive Overview of the Clinical Pharmacokinetics of Clobazam , 2018, Journal of clinical pharmacology.

[13]  D. Ochoa,et al.  Effect of Polymorphisms on the Pharmacokinetics, Pharmacodynamics and Safety of Sertraline in Healthy Volunteers , 2018, Basic & clinical pharmacology & toxicology.

[14]  Y. Daali,et al.  Complex Drug–Drug–Gene–Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives , 2018, Clinical Pharmacokinetics.

[15]  M. Relling,et al.  Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group , 2018, Clinical pharmacology and therapeutics.

[16]  G. Nomikos,et al.  Vortioxetine: Clinical Pharmacokinetics and Drug Interactions , 2017, Clinical Pharmacokinetics.

[17]  Xiaoping Chen,et al.  The pharmacogenomics of valproic acid , 2017, Journal of Human Genetics.

[18]  K. Sangkuhl,et al.  Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update , 2017, Clinical pharmacology and therapeutics.

[19]  G. Logroscino,et al.  Pharmacogenetics of neurological and psychiatric diseases at older age: has the time come? , 2017, Expert opinion on drug metabolism & toxicology.

[20]  S. Namazi,et al.  A comparison of five common drug–drug interaction software programs regarding accuracy and comprehensiveness , 2016, Journal of research in pharmacy practice.

[21]  Ales Belic,et al.  Optimization of Clonazepam Therapy Adjusted to Patient’s CYP3A Status and NAT2 Genotype , 2016, The international journal of neuropsychopharmacology.

[22]  J. Markowitz,et al.  Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition. , 2016, Journal of child and adolescent psychopharmacology.

[23]  S. Janković,et al.  CYP1A2 genotype affects carbamazepine pharmacokinetics in children with epilepsy , 2016, European Journal of Clinical Pharmacology.

[24]  Shengying Qin,et al.  Association studies of genomic variants with treatment response to risperidone, clozapine, quetiapine and chlorpromazine in the Chinese Han population , 2015, The Pharmacogenomics Journal.

[25]  K. Sangkuhl,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors , 2015, Clinical pharmacology and therapeutics.

[26]  C. Jang,et al.  Effects of CYP2C19 Genetic Polymorphisms on Atomoxetine Pharmacokinetics , 2014, Journal of clinical psychopharmacology.

[27]  J J Swen,et al.  Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants , 2013, Clinical pharmacology and therapeutics.

[28]  E. Prommer.  Role of Haloperidol in Palliative Medicine , 2012, The American journal of hospice & palliative care.

[29]  G. Novelli,et al.  The Pharmacogenomic HLA Biomarker Associated to Adverse Abacavir Reactions: Comparative Analysis of Different Genotyping Methods , 2012, Current genomics.

[30]  R. Bergstrom,et al.  Duloxetine: clinical pharmacokinetics and drug interactions. , 2011, Clinical pharmacokinetics.

[31]  J. Biernacka,et al.  Effect of Cytochrome P450 Enzyme Polymorphisms on Pharmacokinetics of Venlafaxine , 2011, Therapeutic drug monitoring.

[32]  O. Spigset,et al.  Characterisation of zuclopenthixol metabolism by in vitro and therapeutic drug monitoring studies , 2010, Acta psychiatrica Scandinavica.

[33]  W. Daniel,et al.  Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver--A comparison with other phenothiazines. , 2010, Biochemical pharmacology.

[34]  K. Nakagawa,et al.  Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy , 2010, Pharmaceuticals.

[35]  L. Wienkers,et al.  Selection of Alternative CYP3A4 Probe Substrates for Clinical Drug Interaction Studies Using In Vitro Data and In Vivo Simulation , 2010, Drug Metabolism and Disposition.

[36]  Jian Cai,et al.  Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. , 2009, Current medicinal chemistry.

[37]  K. Nakagawa,et al.  Population Estimation Regarding the Effects of Cytochrome P450 2C19 and 3A5 Polymorphisms on Zonisamide Clearance , 2008, Therapeutic drug monitoring.

[38]  J. Bauman,et al.  Comparison of the Bioactivation Potential of the Antidepressant and Hepatotoxin Nefazodone with Aripiprazole, a Structural Analog and Marketed Drug , 2008, Drug Metabolism and Disposition.

[39]  Mellar P. Davis.  Does trazodone have a role in palliating symptoms? , 2007, Supportive Care in Cancer.

[40]  M. Murray.  Role of CYP pharmacogenetics and drug‐drug interactions in the efficacy and safety of atypical and other antipsychotic agents , 2006, The Journal of pharmacy and pharmacology.

[41]  E. Leinonen,et al.  A review of the pharmacological and clinical profile of mirtazapine. , 2006, CNS drug reviews.

[42]  R. Holley-Shanks,et al.  Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics. , 2004, Pharmacogenetics.

[43]  J. Brockmöller,et al.  Cytochrome P450 3A4 messenger ribonucleic acid induction by rifampin in human peripheral blood mononuclear cells: Correlation with alprazolam pharmacokinetics , 2003, Clinical pharmacology and therapeutics.

[44]  K. Wernecke,et al.  Effects of Polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on Trimipramine Pharmacokinetics , 2003, Journal of clinical psychopharmacology.

[45]  R. Obach,et al.  Ziprasidone Metabolism, Aldehyde Oxidase, and Clinical Implications , 2003, Journal of clinical psychopharmacology.

[46]  P. Fernández-Salguero,et al.  Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype , 2003, European Journal of Clinical Pharmacology.

[47]  J. Brockmöller,et al.  Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. , 2002, Pharmacogenetics.

[48]  B. Ring,et al.  Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[49]  S. Ekins,et al.  (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[50]  S. Kennedy,et al.  Citalopram--a review of pharmacological and clinical effects. , 2000, Journal of psychiatry & neuroscience : JPN.

[51]  C. Beasley,et al.  Olanzapine. Pharmacokinetic and pharmacodynamic profile. , 1999, Clinical pharmacokinetics.

[52]  T. Terao,et al.  An active metabolite of carbamazepine, carbamazepine-10,11-epoxide, inhibits ion channel-mediated catecholamine secretion in cultured bovine adrenal medullary cells , 1998, Psychopharmacology.

[53]  R. Goldberg,et al.  Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. , 1996, The American journal of emergency medicine.

[54]  C. Bonfils,et al.  Oxidative metabolism of zolpidem by human liver cytochrome P450S. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[55]  Chiara Broccanello,et al.  QuantStudio™ 12K Flex OpenArray® System as a Tool for High-Throughput Genotyping and Gene Expression Analysis. , 2020, Methods in molecular biology.

[56]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[57]  Niranjan Rao,et al.  The Clinical Pharmacokinetics of Escitalopram , 2007, Clinical pharmacokinetics.

[58]  K. Goa,et al.  Oxcarbazepine: a review of its use in children with epilepsy. , 2003, Paediatric drugs.

[59]  C. Nemeroff,et al.  Clinical Pharmacokinetics of Quetiapine , 2001, Clinical pharmacokinetics.

[60]  D. Tweedie,et al.  Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. , 2000, British journal of clinical pharmacology.

[61]  K. Shadan,et al.  Available online: , 2012 .